To our knowledge this is the first clinical trial aiming at eliciting CD4+ T cell dominated immune responses against the clonal driver mutation H3K27M in diffuse midline glioma and the first trial to investigate the combined treatment with H3K27M-specific peptide vaccine, RT and anti-PD-L1 therapy in DMG. Here, CD274 is linked to diffuse midline glioma.